The reporter learned from Sanpower Group that on January 10th, Beijing time (January 9th, US West Coast time), China’s private enterprise Sancell Group and Valeant, a well-known global biomedical company, reached an equity acquisition agreement in San Francisco to acquire the latter’s US The 100% stake in biopharmaceutical company Dendreon has become the world's first prostate cancer cell immunotherapy Provenge owner, the only original drug acquired by Chinese companies in the United States, and has become one of the world's leading high-end precision medical industry.
It is reported that the acquisition transaction amounted to 819 million US dollars, which also set the largest transaction record for Chinese companies to acquire US drugs. In 2016, Provenge's profit was about 120 million US dollars, and the price-earnings ratio was about 8 times. In the future, it has great application prospects in China, Asia and Europe.
On April 29, 2010, the US FDA officially approved Dendreon's Provenge to treat asymptomatic or mildly symptomatic metastatic castration-resistant (hormone-refractory) prostate cancer, becoming the first to be approved by the US FDA. Autoimmune cell therapy for prostate cancer is also the only cellular immunotherapy currently used to treat advanced prostate cancer.
Traditional treatments for cancer, such as surgery, radiation therapy, and drug therapy, have certain limitations. With the development of medicine, immunotherapy has become another breakthrough therapy for cancer treatment. Provenge uses the patient's own immune system to fight against malignant tumors, and treats prostate cancer by reprogramming the body's own immune cells to identify and attack advanced prostate cancer cells. Provenge is the world's first systematically clinically proven immune system that can effectively curb tumors and prolong life, thus opening the door to immunotherapy.
The median survival of patients receiving Provenge immunotherapy was 25.8 months, while the median survival of patients who did not receive this drug was only 21.7 months, and the median survival increased by 4.1. In most months, most patients can be extended for more than 12 months, especially in patients with prostate cancer who have a low tumor burden. It is reported that Provenge's 4.1-month survival benefit is comparable to other small-molecule oral drugs for prostate cancer, but it is safer, with fewer side effects on patients, similar to cold symptoms, relieved in 1-2 days. , significantly improve the quality of life of patients. Synchronous treatment with other drugs is not excluded during treatment.
Medical Equipment Disposal,Syringes Needles Sizes,Disposable Syringe,Insulin Syringe
FOSHAN PHARMA CO., LTD. , https://www.forepharm.com